Vivos Therapeutics (VVOS)
(Delayed Data from NSDQ)
$3.44 USD
+0.10 (2.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VVOS 3.44 +0.10(2.99%)
Will VVOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VVOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VVOS
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
VVOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for VVOS
VVOS falls 5.11% on September 19, leaving the technical picture intact
Bullish Engulfing appears for VVOS after 3.53% move
Vivos Therapeutics (VVOS) Achieves Milestone in Pediatric Sleep Apnea Treatment
Vivos Therapeutics announces trial results in pediatric OSA treatment
Vivos Therapeutics announces trial results in pediatric OSA treatment